Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Not Applicable

Withdrawn

• Conditions: Parkinson's Disease

• Registration Number: NCT00640952
• Lead Sponsor: Baylor College of Medicine

Brief Summary

The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-08
• Study First Submitted: 2007-12-28
• Study First Submitted QC: 2008-03-20
• Study First Posted: 2008-03-21
• Primary Completion: 2008-09
• Study Completion: 2008-09
• Status Verified: 2015-11
• Last Update Submitted: 2015-11-10
• Last Update Posted: 2015-11-13

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Idiopathic Parkinson's disease
2. Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist)
3. Able and willing to complete Rating Scales
4. Presence of one or more compulsive behavior based on responses to Rating Scales (defined as >5 on the SOGS; >17 on the YBOCS-SV and YBOCS-CUV; >1.7 on the SCS for women and >2.1 on the SCS for men; >15 on the YBOCS-BE, >5.5 on the CQ).
5. Written informed consent

Inclusion criteria (controls):

1. No significant psychiatric disease
2. Able and willing to complete Rating Scales
3. Written informed consent

Exclusion Criteria

1. No anticipated need for adjustment of medications for Parkinson's disease
2. Current participation in another clinical study
3. History of unstable psychiatric disease (as determined by the Principal Investigator)
4. Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
safety and efficacy compared to baseline scores	6 months

Secondary Outcome Measures

Name	Time	Method
change from baseline assessment tools used in the study	6 months

Trial Locations

Locations (1)

PDCMDC 6550 Fannin, Suite 1801; 🇺🇸 Houston, Texas, United States